A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis.
about
RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitorsKnockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer?Immunocompromised and immunocompetent mouse models for head and neck squamous cell carcinomaMicrotubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cellsSmall molecule inhibitors of the Candida albicans budded-to-hyphal transition act through multiple signaling pathwaysInactivation of farnesyltransferase and geranylgeranyltransferase I by caspase-3: cleavage of the common alpha subunit during apoptosisFarnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells.Targeting protein prenylation for cancer therapyHER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancerHyperactive Ras as a therapeutic target in neurofibromatosis type 1.Farnesyltransferase inhibitors. Preclinical development.Selective inhibition of ras-transformed cell growth by a novel fatty acid-based chloromethyl ketone designed to target Ras endoprotease.Farnesyltransferase inhibitor-induced regression of mammary tumors in TGF alpha and TGF alpha/neu transgenic mice correlates with inhibition of map kinase and p70s6 kinase phosphorylation.Apoptosis in cancer.On the physiological importance of endoproteolysis of CAAX proteins: heart-specific RCE1 knockout mice develop a lethal cardiomyopathy.The ubiquitin E3 ligase RAUL negatively regulates type i interferon through ubiquitination of the transcription factors IRF7 and IRF3.Genetically engineered mice as experimental tools to dissect the critical events in breast cancerIsoprenoids and related pharmacological interventions: potential application in Alzheimer's disease.Advances in molecular carcinogenesis: current and future use of mouse models to screen and validate molecularly targeted anticancer drugs.Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.Molecular biological design of novel antineoplastic therapies.Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level.Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells.Establishing a link between oncogenes and tumor angiogenesisFarnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomasSEARCHBreast: a new resource to locate and share surplus archival material from breast cancer animal models to help address the 3Rs.Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.Caution! Analyze transcripts from conditional knockout allelesInhibitors of cellular signalling are cytotoxic or block the budded-to-hyphal transition in the pathogenic yeast Candida albicans.Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents.The mutant p53 mouse as a pre-clinical model.Protein lipid modifications--More than just a greasy ballast.Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration.The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents.Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli.Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta.Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines.Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway.
P2860
Q24552386-579D8D08-8BAA-4BE1-BFA0-0F6E94E26739Q24802378-C1E791E3-81B4-410C-A6AA-C169AED521C3Q26766538-35EDB954-91E0-4C6F-91AE-E5712D81C2A8Q28371622-9ABBB55D-8804-4B33-AAFC-433FA6B2E1F7Q28477230-C75B0A55-9C2F-475F-9378-ED0E013D0633Q28580707-7331D526-20EF-4BEA-B1A2-3795A8601608Q33583266-3228DEFF-2A56-49BC-BC7C-FB3986E09ECBQ33679239-C62620E1-DDEA-41CF-BCE5-D8C353D636DBQ33694931-EC2BE236-C80B-484A-A4DF-F5948ABF48E8Q33723856-E21E8265-48E8-441B-813E-EB2953B70241Q33833364-DD65DDF4-6D97-471A-8A66-1F747998FA1CQ33833368-F472FD60-5231-4BE9-BF8E-9CF5A3726F87Q33833455-DE867087-6226-4B9A-AD0B-63EB3A0A4ACAQ33846227-344DFB1A-7DCB-4CFA-A56E-5882E5EDBD35Q34277651-4BE8D9C3-02A4-4E8F-989C-3261EDA2EC63Q34449547-6E644E4D-ED8F-4E0B-93D8-A4FAE90DD82CQ35146602-B4F1F59B-6545-499B-AA13-90A07EB20B59Q35634151-26E42874-0D86-44B5-805E-3AF40EE7A39FQ35730957-98046E99-E7CE-43F6-A724-135222FF8C6DQ35760817-084DED85-11F0-4DB6-9E28-1913F184A8B7Q35790781-AC52E7A0-F90D-44A0-86CD-3F138E99A69BQ35990656-56403D74-540D-4AB7-85E6-323A128DF31DQ36006469-D1C18A6E-0296-4F1F-B1F6-EE39166BD43FQ36438366-63016CBA-1CC1-4488-9678-5AFB06D1C3DEQ36693797-00E6A4F5-939D-44FE-ABAC-596715291595Q36814409-42D9EA49-14BC-49A4-9E6C-1181F7A68727Q37137960-7183497A-083E-4AB4-AD57-6A40CAD55F67Q37184386-874609ED-8DA6-4B01-AF37-F1639C64E726Q37343625-83D6A969-75AF-4326-A5B3-EA7B3AC81C45Q37472121-09CDE30E-13F9-41D0-9CA1-07FF6FE65619Q38074014-E8E297BD-80CA-4C30-A1D5-718F9039D483Q38673481-9605678C-C101-4DB8-B7A9-3CEE9AC6BD2CQ39444763-D7E8CEB7-ABFC-4D33-BFC2-3ADF8B9A5596Q40478997-40FFC809-CA38-4184-842B-CE3F486DAC22Q40726065-6820B7CB-0065-4FA7-AB53-D1136FE4F56AQ40778601-76B043E5-3702-42E0-BD0D-67E8683D299AQ40831741-B93BAA98-A4EF-4111-B8A5-82360AAC208CQ40837781-990FDB19-24B1-41DC-BA30-4DD9DCD43AC4Q40871201-EB8BF24C-A34F-4ED2-B866-ED4C5B5C1679Q40973684-15002E29-94AB-402F-8B4F-21AC0768B142
P2860
A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
A farnesyltransferase inhibito ...... l cycle control and apoptosis.
@ast
A farnesyltransferase inhibito ...... l cycle control and apoptosis.
@en
type
label
A farnesyltransferase inhibito ...... l cycle control and apoptosis.
@ast
A farnesyltransferase inhibito ...... l cycle control and apoptosis.
@en
prefLabel
A farnesyltransferase inhibito ...... l cycle control and apoptosis.
@ast
A farnesyltransferase inhibito ...... l cycle control and apoptosis.
@en
P2093
P2860
P356
P1476
A farnesyltransferase inhibito ...... l cycle control and apoptosis.
@en
P2093
Barrington RE
Hamilton K
Hundley JE
Koester SK
P2860
P356
10.1128/MCB.18.1.85
P407
P577
1998-01-01T00:00:00Z